Alps Advisors Inc. boosted its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 9.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 120,544 shares of the biopharmaceutical company’s stock after acquiring an additional 10,381 shares during the quarter. Alps Advisors Inc. owned 0.10% of ACADIA Pharmaceuticals worth $4,541,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Ray Gerald L & Associates Ltd. boosted its position in ACADIA Pharmaceuticals by 1.3% during the 3rd quarter. Ray Gerald L & Associates Ltd. now owns 199,260 shares of the biopharmaceutical company’s stock worth $7,506,000 after acquiring an additional 2,480 shares during the period. Legato Capital Management LLC boosted its position in ACADIA Pharmaceuticals by 321.9% during the 3rd quarter. Legato Capital Management LLC now owns 33,748 shares of the biopharmaceutical company’s stock worth $1,271,000 after acquiring an additional 25,748 shares during the period. Pictet Asset Management Ltd. boosted its position in ACADIA Pharmaceuticals by 40.8% during the 3rd quarter. Pictet Asset Management Ltd. now owns 1,332,055 shares of the biopharmaceutical company’s stock worth $50,179,000 after acquiring an additional 386,217 shares during the period. Handelsbanken Fonder AB boosted its position in ACADIA Pharmaceuticals by 7.3% during the 3rd quarter. Handelsbanken Fonder AB now owns 190,000 shares of the biopharmaceutical company’s stock worth $7,157,000 after acquiring an additional 13,000 shares during the period. Finally, Nationwide Fund Advisors boosted its position in ACADIA Pharmaceuticals by 42.4% during the 3rd quarter. Nationwide Fund Advisors now owns 38,350 shares of the biopharmaceutical company’s stock worth $1,445,000 after acquiring an additional 11,410 shares during the period. Hedge funds and other institutional investors own 97.01% of the company’s stock.

A number of equities research analysts have recently weighed in on ACAD shares. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of ACADIA Pharmaceuticals in a research note on Wednesday. Cowen and Company reaffirmed a “buy” rating and set a $46.00 price target on shares of ACADIA Pharmaceuticals in a research note on Tuesday, November 7th. Zacks Investment Research downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Jefferies Group LLC reaffirmed a “buy” rating and set a $47.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 12th. Finally, Leerink Swann reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Monday, October 9th. Six research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $47.73.

WARNING: This article was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/11/12/acadia-pharmaceuticals-inc-acad-position-boosted-by-alps-advisors-inc.html.

Shares of ACADIA Pharmaceuticals Inc. (ACAD) traded down $0.56 during midday trading on Friday, reaching $28.60. The company’s stock had a trading volume of 1,805,900 shares, compared to its average volume of 1,661,195. ACADIA Pharmaceuticals Inc. has a 52 week low of $24.31 and a 52 week high of $41.20.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.10. The company had revenue of $35.58 million for the quarter, compared to the consensus estimate of $32.03 million. ACADIA Pharmaceuticals had a negative return on equity of 67.68% and a negative net margin of 320.71%. The company’s revenue for the quarter was up 571.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.61) EPS. equities analysts anticipate that ACADIA Pharmaceuticals Inc. will post -2.44 earnings per share for the current year.

In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 26,507 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $34.87, for a total value of $924,299.09. Following the transaction, the executive vice president now directly owns 94,163 shares of the company’s stock, valued at approximately $3,283,463.81. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 22.25% of the company’s stock.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.